(Q53058730)

10 May 2018

title

MYC protein expression is associated with poor prognosis in diffuse large B cell lymphoma patients treated with RCHOP chemotherapy. (English)

1 reference

10 May 2018

1 reference

Jing Wang

2

0 references

author name string

Min Zhou

1

1 reference

10 May 2018

Jian Ouyang

3

1 reference

10 May 2018

Jing-yan Xu

4

1 reference

10 May 2018

Bing Chen

5

1 reference

10 May 2018

Qi-guo Zhang

6

1 reference

10 May 2018

Rong-fu Zhou

7

1 reference

10 May 2018

Yong-gong Yang

8

1 reference

10 May 2018

Xiao-yan Shao

9

1 reference

10 May 2018

Yong Xu

10

1 reference

10 May 2018

Ya-mei Chen

11

1 reference

10 May 2018

Xiang-shan Fan

12

1 reference

10 May 2018

Hong-yan Wu

13

1 reference

10 May 2018

publication date

11 April 2014

1 reference

10 May 2018

published in

Tumor Biology

1 reference

10 May 2018

volume

35

1 reference

10 May 2018

issue

7

1 reference

10 May 2018

page(s)

6757-6762

1 reference

10 May 2018

https://scigraph.springernature.com/pub.10.1007/s13277-014-1907-z

exact match

0 references

cites work

MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1907-Z

Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1907-Z

A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1907-Z

Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1907-Z

Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1907-Z

Immunohistochemical detection of MYC protein correlates with MYC gene status in aggressive B cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1907-Z

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1907-Z

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1907-Z

Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1907-Z

Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1907-Z

Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1907-Z

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Pr

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1907-Z

The interplay between c-Myc oncogene expression and circulating vascular endothelial growth factor (sVEGF), its antagonist receptor, soluble Flt-1 in diffuse large B cell lymphoma (DLBCL): relationship to patient outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1907-Z

Reverse engineering of regulatory networks in human B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1907-Z

Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1907-Z

Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1907-Z

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-1907-Z

Paramount prognostic factors that guide therapeutic strategies in diffuse large B-cell lymphoma

21 January 2018

1 reference

12 December 2020

MYCtranslocation-negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation

1 reference

12 December 2020

MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma

1 reference

12 December 2020

Altered subcellular localization of c-Myc protein identifies aggressive B-cell lymphomas harboring a c-MYC translocation

1 reference

12 December 2020

10.1007/S13277-014-1907-Z

Identifiers

DOI

1 reference

10 May 2018

1 reference

10 May 2018